Articles related to LUNG CANCER

The updated ASCO guidelines for stage IV NSCLC provide new treatment recommendations based on the latest evidence. Explore these changes and their potential impact on patient care.

The KEYNOTE-789 study results have sparked a debate on the role of immunotherapy in treating stage IV EGFR-mutated NSCLC. While the study did not show a significant benefit of adding pembrolizumab to chemotherapy, experts agree that the potential role of immunotherapy, particularly in combination with anti-angiogenic therapy, should not be completely dismissed.

Dr. Janet L. Espirito’s groundbreaking research demonstrates how real-world data can effectively be used to evaluate therapeutic responses in patients with mNSCLC. Discover how this innovative approach could shape the future of oncology treatment evaluation.

The results of the WU-KONG6 study offer hope for NSCLC patients with EGFR exon20 insertion mutations, demonstrating the substantial antitumor efficacy of sunvozertinib.

Clinicians are eyeing the increased survival odds associated with Tagrisso, a targeted therapy for early-stage NSCLC patients. This revelation may shift the narrative on post-operative treatment protocols, promoting wider acceptance in oncological circles.

Understand the profound implications of Dr. Vidal’s latest research on racial disparities in NGS testing for advanced non-small cell lung cancer, revealing a systemic issue that spans across practices and extends to the level of individual physicians.